Immunitybio, Inc.
Records under this name other than the patents Immunitybio, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 90 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,053,299 | Superkine Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,736,921 | Genetically Modified NK-92 Cells and Monoclonal Antiboides for the Treatment of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 11,000,550 | Genetically Modified NK-92 Cells and Monoclonal Antiboides for the Treatment of Cancer Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,207,350 | Genetically Modified NK-92 Cells and Monoclonal Antibodies for the Treatment of Cancer Formerly held In force · Low confidence | In force | Low confidence | |
| US 11,439,697 | Nant Cancer Vaccine Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,491,201 | Maximizing T-Cell Memory and Compositions and Methods Therefor Formerly held In force · High confidence | In force | High confidence | |
| US 12,215,350 | Mononuclear Cell Derived NK Cells Formerly held In force · High confidence | In force | High confidence | |
| US 11,684,668 | Replication-Defective Adenoviruses Comprising Nucleic Acids Encoding SARS-COV-2 S Glycoprotein and Modified N Protein Comprising an Endosomal Targeting Sequence Formerly held In force · High confidence | In force | High confidence | |
| US 10,885,173 | Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods Formerly held In force · High confidence | In force | High confidence | |
| US 11,048,788 | Content Authentication and Validation via Multi-Factor Digital Tokens, Systems, and Methods Formerly held In force · High confidence | In force | High confidence |